Engineers Gate Manager’s TG Therapeutics TGTX Stock Holding History

Engineers Gate Manager’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$589K	Buy	+10,727	New	+$439K	0.01%	1407
2026 Q1	–	Sell	-95,309	Closed	-$2.84M	–	2562
2025 Q4	$2.84M	Buy	95,309 +14,071	+17%	+$460K	0.03%	544
2025 Q3	$2.93M	Buy	81,238 +63,746	+364%	+$2.1M	0.03%	590
2025 Q2	$630K	Buy	17,492 +10,148	+138%	+$378K	0.01%	1374
2025 Q1	$290K	Buy	+7,344	New	+$247K	﹤0.01%	1731
2024 Q4	–	Sell	-12,894	Closed	-$302K	–	2571
2024 Q3	$302K	Sell	12,894 -44,139	-77%	-$964K	0.01%	1618
2024 Q2	$1.01M	Buy	+57,033	New	+$910K	0.02%	880
2024 Q1	–	Sell	-91,396	Closed	-$1.56M	–	2298
2023 Q4	$1.56M	Sell	91,396 -24,598	-21%	-$286K	0.04%	565
2023 Q3	$970K	Buy	+115,994	New	+$1.62M	0.04%	723
2020 Q3	–	Sell	-12,151	Closed	-$237K	–	1982
2020 Q2	$237K	Buy	12,151 +1,238	+11%	+$19.9K	0.01%	1347
2020 Q1	$107K	Buy	+10,913	New	+$138K	0.01%	1405

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Engineers Gate Manager's TGTX Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in TG Therapeutics (TGTX) in Q2 2026: 10,727 shares worth $589K. The stake represents 0.01% of the portfolio and ranks #1407 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in TGTX as recently as Q4 2025.

Engineers Gate Manager first reported a position in TGTX in Q1 2020 and has held it in 11 quarters since. The position peaked at $2.93M in Q3 2025. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Engineers Gate Manager held 10,727 shares of TG Therapeutics worth $589K as of Q2 2026.
TG Therapeutics was a new Engineers Gate Manager position in Q2 2026.
TG Therapeutics made up 0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1407 holding.
Engineers Gate Manager first reported a position in TG Therapeutics in Q1 2020 and has held it in 11 quarters since.
Engineers Gate Manager's TG Therapeutics position peaked at $2.93M in Q3 2025.
427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.